Plus Therapeutics (PSTV) Net Cash Flow (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Net Cash Flow data on file, last reported at -$5.7 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$5.7 million, down 158.58% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.8 million (down 198.26% YoY), and the FY2025 annual result was $8.7 million, up 202.41% from the prior year.
• Net Cash Flow retreated to -$5.7 million in Q1 2026 per PSTV's latest filing, from -$4.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $11.1 million in Q3 2025 and troughed at -$7.6 million in Q2 2025.
• A 5-year average of -$904588.2 and a median of -$2.1 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow sank 3423.42% in 2024, then surged 400.19% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$2.1 million in 2022, then fell by 14.26% to -$2.5 million in 2023, then jumped by 53.22% to -$1.1 million in 2024, then plunged by 296.6% to -$4.5 million in 2025, then retreated by 26.09% to -$5.7 million in 2026.
• Business Quant data shows PSTV's Net Cash Flow at -$5.7 million in Q1 2026, -$4.5 million in Q4 2025, and $11.1 million in Q3 2025.